Inhibitex Stock up 150% in Pre-Market (BMY, INHX)
Bristol-Myers Squibb (NYSE: BMY) will pay $2.5 billion in cash (a 163% premium to Friday’s closing price) for hepatitis C drug developer Inhitibex Inc. (NASDAQ: INHX). Contact [email protected] for any questions or corrections.
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Bristol-Myers Squibb (NYSE: BMY) will pay $2.5 billion in cash (a 163% premium to Friday’s closing price) for hepatitis C drug developer Inhitibex Inc. (NASDAQ: INHX).
Contact [email protected] for any questions or corrections.
Paul Ausick has been writing for 247Wallst.com for more than a decade. He has written extensively on investing in the energy, defense, and technology sectors. In a previous life, he wrote technical documentation and managed a marketing communications group in Silicon Valley.
He has a bachelor's degree in English from the University of Chicago and now lives in Montana, where he fishes for trout in the summer and stays inside during the winter.
